Alzheimer Stage 5 - Search News

Alzheimer, Novo

Novo Nordisk Alzheimer's Drug Trials Fail in Blow to Weight-Loss Giant

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli Lilly's Kisunla are the only treatments approved in the United States to slow progression of Alzheimer's disease. Both drugs require infusions or injections and can cause significant side effects.

· 21h

Novo Nordisk stock slides as its Alzheimer’s drug trials fail

· 23h · on MSN

Novo Nordisk shares plunge as oral semaglutide Alzheimer’s trial fails to show clinical benefit

Scientific American · 18h

GLP-1 Pill Fails to Slow Alzheimer’s Progression in Clinical Trial

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression

· 22h

Novo Nordisk says Alzheimer's trial with older GLP-1 drug fails

· 20h

Novo Nordisk Stock Falls. Why Its Alzheimer’s Trial News Is Hitting Shares.

Rolling Out

The 7 stages of Alzheimer’s disease explained

Alzheimer’s disease doesn’t arrive suddenly. Instead, it emerges slowly, beginning with subtle changes that might be dismissed as normal aging before progressing through increasingly serious stages of cognitive and functional decline. For families and ...

Does Novo Nordisk's (CPSE:NOVO B) Alzheimer’s Setback Challenge Its Long-Term Diversification Ambitions?

On November 24, 2025, Novo Nordisk announced top-line results from its phase 3 evoke and evoke+ trials, revealing that oral semaglutide did not show superiority over placebo in slowing progression of early-stage symptomatic Alzheimer's disease,

2don MSN

Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1

Eli Lilly (LLY) rally comes under scrutiny as Novo Nordisk (NVO) readies key late-stage trial results for its GLP-1 pill Rybelsus in Alzheimer's. Read more here.

Rolling Out

5 critical signs of Alzheimer’s final progression

The final stages of Alzheimer’s disease represent one of the most challenging periods for families watching their loved ones navigate this devastating condition. Understanding the critical signs that indicate progression into the end stages can help ...

Taiwan News

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were randomised, double-blinded,

Asianet Newsable on MSN

Novo Nordisk Stock Tumbles: HSBC Downgrades After ‘Lottery Ticket’ Alzheimer’s Bet Fails, But Retail Traders Call Selloff ‘Ridiculous’

HSBC cut Novo Nordisk to ‘Hold’ after its EVOKE Alzheimer’s trials showed no slowing of disease progression versus placebo.